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In mammals, the three classical ras genes encode four highly homologous proteins, N-Ras, H-Ras, and the
isoforms K-Ras 4A and 4B. Previous studies have shown that K-ras is essential for mouse development and that
while K-ras 4A and 4B are expressed during development, K-ras 4A expression is regulated temporally and
spatially and occurs in adult kidney, intestine, stomach, and liver. In the present study, the pattern of K-ras
4A expression was examined in a wide range of wild-type adult mouse tissues, and gene targeting was used to
generate K-ras 4A-deficient mice to examine its role in development. It was found that K-ras 4A is also
expressed in uterus, lung, pancreas, salivary glands, seminal vesicles, bone marrow cells, and cecum, where it
was the major K-Ras isoform expressed. Mating between K-rastm4A/ mice produced viable K-rastm4A/tm4A
offspring with the expected Mendelian ratios of inheritance, and these mice expressed the K-ras 4B splice
variant only. K-rastm4A/tm4A mice were fertile and showed no histopathological abnormalities on inbred
(129/Ola) or crossbred (129/Ola C57BL/6) genetic backgrounds. The results demonstrate that K-Ras 4A, like
H- and N-Ras, is dispensable for normal mouse development, at least in the presence of functional K-Ras 4B.
The three classical mammalian ras genes, K-, N-, and H-ras,
encode proteins that are members of the guanine nucleotide
binding protein superfamily (8). Ras proteins are small (21
kDa) GTPases which cycle between inactive (GDP-bound) and
active (GTP-bound) conformations at the plasma membrane,
by interaction with a variety of guanine nucleotide exchange
factors and GTPase activating proteins in response to stimu-
lation by a diverse array of cell surface receptors, including the
epidermal growth factor receptor and cytokine receptors such
as interleukin-2 (14). Following activation, Ras proteins bind
and activate a plethora of downstream effector proteins, in-
cluding Raf kinases and phosphatidylinositol 3-kinases, and by
this means control many cellular functions, including prolifer-
ation, differentiation, migration, and apoptosis (4, 11, 28).
Activating point mutations leading to constitutive activation
of the Ras proteins are associated with some 30% of all human
malignancies (1), and these mutations render Ras insensitive
to the regulatory action of GTPase activating proteins, leading
to excessive and inappropriate signaling, resulting in the pro-
motion of cellular transformation. However, while mutation-
ally active ras genes are generally believed to act as dominant
oncogenes, recent reports indicate that wild-type K- and N-Ras
proteins have tumor suppressor activity (7, 32). Thus, K- and
N-ras appear to exert a dual function in that they promote
cancer development as gain-of-function oncogenes when mu-
tated and inhibit cancer by tumor suppressor activity when wild
type (proto-oncogene).
The high degree of homology between Ras proteins suggests
that functional redundancy may exist among these proteins, yet
mounting evidence exists for unique roles for the ras gene
family members. For example, most human cancers with ras
activating mutations are associated exclusively with a particular
ras gene, suggesting tissue-specific activity: K-ras mutations are
prevalent in lung (30%), colon (40%), and pancreatic
(90%) cancers, while H-ras and N-ras activating mutations
are associated with bladder cancer and myeloid leukemia, re-
spectively (1). Furthermore, while N-ras and H-ras are dispens-
able for development both individually and in combination (10,
26), mice harboring a homozygous K-ras null mutation (K-
ras/) are not viable and die between day 12.5 post coitum
and term (depending on the genetic background) due to car-
diac, liver, neurological, and hematopoietic defects (18, 19).
Thus, of the classical ras gene family members (K-, N-, and
H-ras), only K-ras is necessary for embryonic development.
However, the findings that (i) N-ras/ mice are healthy but
N-ras/, K-ras/ mice die in utero (18), (ii) K-ras/
N-ras/ mice exhibit a more severe phenotype than K-ras/
mice (18), and (iii) fewer than expected H-ras/ N-ras/
mice survive embryogenesis (10) underline the essential role
for K-Ras in development and imply partial functional overlap
between different Ras proteins.
Understanding the role(s) of K-Ras in development and
tissue function is an important route to gain insight as to how
K-ras activating mutations promote neoplastic change. How-
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ever, this is complicated by the fact that the K-ras gene encodes
two protein isoforms, K-Ras 4A and K-Ras 4B, of 189 and 188
residues, respectively, by alternative splicing of the fourth cod-
ing exons 4A and 4B, and K-ras activating mutations that
usually affect codons 12, 13, and 61 jointly affect both isoforms
(5, 9, 21). The isoforms differ significantly at their C termini
after residue 165, including the hypervariable domains and
CAAX motifs. These regions are involved in membrane asso-
ciation, which is essential for Ras function (16) via a series of
posttranslational modifications, which include isoprenylation,
endoproteolysis, and methylation (25). However, these modi-
fications differ between the isoforms due to the sequence dif-
ferences at the hypervariable domain: K-Ras 4A, like N- and
H-Ras, is palmitoylated at cysteine residues upstream of the
CAAX motif, which are replaced with a polylysine domain in
K-Ras 4B.
The difference in C-terminal modifications of Ras proteins
leads to alternative trafficking pathways to the plasma mem-
brane (3) and ultimately localization to different plasma mem-
brane microdomains (23, 24). Indeed, reports that H-, N-, and
K-Ras differentially affect Raf-1, phosphatidylinositol 3-kinase,
and Rac (28, 29, 31) suggest that they elicit divergent biological
responses by interacting with different subsets of downstream
effectors. Thus, the posttranslational differences between K-
Ras 4A and K-Ras 4B could affect their membrane localization
and, therefore, interaction with different membrane targets.
The specific association between K-Ras 4B and the guanine
nucleotide exchange factor Smg GDS (27) and reports that the
oncogenic mutant (G12V) K-Ras 4A and 4B differ in their
ability to activate Raf-1, induce transformed foci, enable an-
chorage-independent growth, and promote cell migration in
vitro (28) and that K-ras 4A and 4B are expressed differentially
during mouse development and in adult tissues (22, 30) further
suggest that they have distinct biological actions. Thus, the
cooperative effects of both isoforms could account, at least in
part, for the high frequency of K-ras activating mutations in
human cancers.
To examine the role of the individual K-ras splice variants in
development, gene targeting was used to delete exon 4A and
generate K-ras 4A-deficient mice. It was found that
K-rastm4A/tm4A mice are healthy and fertile. The result dem-
onstrates that expression of K-ras 4A is dispensable for normal
development, at least in the presence of functional K-Ras 4B.
MATERIALS AND METHODS
Design of the K-ras 4A targeting vector. A nonisogenic targeting vector
(pPTKiNKi4A) was used to delete exon 4A of K-ras to generate a mutant allele
designated K-rastm4A. The 2.8-kb 5 and the 1.3-kb 3 arms of homology were
isolated by HindIII and XbaI-EcoRI digests, respectively, of an 11.5-kb EcoR1
fragment (from BALB/c mice) stretching from upstream of exon 3 to upstream
of exon 4B (13). The neomycin resistance cassette (containing a phosphoglycer-
ate kinase I promoter) and the herpes simplex virus thymidine kinase gene
cassette were employed for positive and negative selection, respectively (Fig.
1A).
Production of K-rastm4A/ embryonic stem cells. The targeting vector was
linearized with EcoRI, and 150 g of DNA was electroporated (800 V and 3 F,
Gene Pulser, Bio-Rad) into strain 129/Ola-derived HM-1 male mouse embryonic
stem cells, which harbor an inactivating deletion in the X-linked Hprt gene (20).
Homologous recombination in colonies resistant to G418 (300 g/ml; Invitro-
gen) and ganciclovir (2 M; Sigma) was identified initially by PCR and confirmed
by Southern analysis. Embryonic stem cell clones were screened with the primer
set neo22 (5-CGATAGAAGGCGATGCGCTGCGAAT-3) and Px4BA (5-A
TAACTGTACACCTTGTCCTTGACT-3), positioned in the neomycin cassette
and exon 4B, respectively (Fig. 1A), which amplify a 2.1-kb product. The PCR
conditions were 1.0 M each primer (Sigma), 1 PCR buffer (Invitrogen), 1.5
mM MgCl2 (Invitrogen), 200 M each deoxynucleoside triphosphate (Amer-
sham), 1 unit of Taq DNA polymerase (Invitrogen), and 100 ng of genomic
DNA per reaction. Following denaturing for 4 min at 94°C, DNA was amplified
for 45 cycles (94°C for 1 min, 58°C for 1 min, and 72°C for 2.5 min).
Homologous recombination was confirmed by Southern blotting. Genomic
DNA (20 g) was digested with HindIII or PvuII and, following electrophoresis,
was transferred to a nylon membrane (GeneScreen) in denaturing buffer (0.5 M
NaOH, 1.5 M NaCl). The membrane was neutralized and prehybridized at 65°C
for 2 h (10% dextran sulfate, 1%sodium dodecyl sulfate, 6 SSC [1 SSC is 0.15
M NaCl plus 0.015 M sodium citrate], 200 g of herring sperm DNA per ml).
The 3 internal and 5 external probes (Fig. 1A) were labeled with [32P]dCTP by
random priming (Stratagene) and hybridized to the membrane at 65°C overnight.
Membranes were washed at room temperature with 2 SSC (twice for 5 min), at
65°C with 2 SSC–1% sodium dodecyl sulfate (twice for 30 min), then at room
temperature with 0.1 SSC (twice for 30 min). Membranes were exposed to film
overnight at 70°C.
Production of K-Ras 4A-deficient mice. Embryonic stem cells harboring the
heterozygous deletion of exon 4A (K-rastm4A/) were injected into day 3.5 post
coitum C57BL/6 blastocysts, which were implanted into the uteri of day 2.5 post
coitum CD1 pseudopregnant recipients. Male chimeras were mated with 129/Ola
or C57BL/6 females to generate inbred and crossbred lines, and germ line
transmission of embryonic stem cell markers was identified by coat color (light
yellow and agouti, respectively).
Since long-range PCR proved unreliable for analyzing tail biopsy DNA, mice
were genotyped with two different PCRs. In reaction 1, the primer set neo52
(5-GATGCCTGCTTGCCGAATATCATGG-3) and neo22 (5-CGATAGAA
GGCGATGCGCTGCGAAT-3), positioned in the neomycin cassette (Fig. 1A),
amplify a 206-bp product in K-rastm4A/ and K-rastm4A/tm4A mice. In reaction
2, the primer set Px4AS (5-CATTGGTGAGAGAGATCCGACAGTAC-3)
and Px4AA (5-TCACACAGCCAGGAGTCTTTTCTTC-3), positioned in
exon 4A (Fig. 1A), amplify a 72-bp product in wild-type and K-rastm4A/ mice.
In both reactions, DNA was denatured for 4 min at 94°C and amplified for 30
cycles at 94°C for 30 s and 58°C for 30 s. The genotypes were subsequently
confirmed by Southern blotting with internal and external probes as described
above.
In the inbred colony, first-generation K-rastm4A/ males (which do not harbor
the Hprt null mutation) were mated with wild-type 129/Ola mice to generate an
inbred stock that was wild type for Hprt. In the crossbred colony, the Hprt
mutation was allowed to segregate. All animal work was carried out under Home
Office license, with ethically approved methods as set out by the UK Coordinat-
ing Committee on Cancer Research in their guidelines on the Welfare of Ani-
mals in Experimental Neoplasia.
RNA analysis. K-ras 4A and 4B expression was determined in tissues from
adult crossbred (129/Ola  C57BL/6) mice by reverse transcription-PCR (RT-
PCR) with primers positioned within exons 1 and 4B, which amplify both iso-
forms in the same reaction (22). RNA was extracted with Trizol reagent (In-
vitrogen), and first-strand cDNA synthesis was performed with the SuperScript
preamplification system, with 1 to 5 g of RNA (Invitrogen). For each sample,
controls without reverse transcriptase were included and were negative in all
cases.
Histology. Mice were sacrificed by cervical dislocation, and tissues were fixed
overnight in 10% neutral buffered formalin except for the large and small intes-
tines, which were fixed in Methacarn (methanol, chloroform, and glacial acetic
acid, 4:2:1 by volume) overnight. Tissues were wax embedded, and 5-m sections
were cut and stained with hematoxylin and eosin.
RESULTS
Generation of K-ras 4A-deficient mice. The targeting vector
pPTKiNKi4A was designed to replace exon 4A of K-ras with
a neomycin resistance cassette (Fig. 1A). Of 324 embryonic
stem clones screened by PCR, 17 were positive for homologous
recombination, amplifying the correct 2.1-kb PCR product
(Fig. 1B). The genotype of seven of these clones was confirmed
by Southern analysis with a 5 external probe that identified a
5-kb wild-type and a 4-kb targeted band and a 3 internal probe
that identified a 2-kb wild-type and a 6-kb targeted band (Fig.












1C). Of nine chimeras (generated from three different embry-
onic stem cell clones), five transmitted embryonic stem cell-
derived coat color markers through the germ line.
Since the effects of mutations, including the K-ras null mu-
tation (18), can vary greatly with the genetic background, the
consequence of deleting K-ras 4A expression was examined in
inbred (129/Ola) and crossbred (129/Ola  C57BL/6) strains
of mice. The embryonic stem cell-derived offspring were geno-
typed at weaning by PCR (with the primer sets neo22/neo52
and Px4AS/Px4AA, which amplify the neomycin cassette and
exon 4A, respectively; Fig. 2A) and by Southern blotting (with
the 5 external and 3 internal probes; Fig. 2B), and it was
found that K-rastm4A/ and wild-type mice were present in the
expected Mendelian ratio (54 and 61, respectively; 21 	 0.426,
P 	 0.514).
K-ras 4A-deficient mice are healthy and fertile. Offspring
from crosses between K-rastm4A/ mice were genotyped by
PCR (Fig. 2A) and Southern blotting (Fig. 2B). Wild-type,
K-rastm4A/, and K-rastm4A/tm4A offspring were present in
the expected Mendelian ratios on both crossbred (48, 101, and
58, respectively; 22 	 1.087, P 	 0.581) and inbred (11, 20,
and 10, respectively; 22 	 0.073, P 	 0.964) genetic back-
FIG. 1. Targeted deletion of the K-ras 4A splice variant in embryonic stem cells. (A) Schematic representation of the mouse K-ras locus and
the targeting vector used to replace exon 4A. The exons are indicated by open boxes. The neomycin resistance cassette and the herpes simplex virus
thymidine kinase gene cassette were employed as selectable markers. In the targeting vector, the thin line denotes plasmid DNA. The positions
of the 5 external and 3 internal probes (solid boxes) and PCR primers (arrows) used for genotyping are indicated. Restriction enzyme sites: E,
EcoRI; P, PvuII; H, HindIII. (B) Embryonic stem cells were genotyped by PCR with the primer set neo22 and Px4BA, which amplify a 2.1-kb
product in clones that harbor the targeted allele (clones 173, 187, 194, 196, 221, 226, and 248). /, wild-type embryonic stem cells; , PCR
negative control; M, 1-kb DNA ladder showing the 2.0- and 2.1-kb size markers. (C) Confirmation of homologous recombination in embryonic
stem cells by Southern blotting. Following digestion with HindIII, a wild-type 2-kb and a targeted 6-kb fragment were detected with the 3 internal
probe (upper panel). Following digestion with PvuII, a wild-type 5-kb and a targeted 4-kb band were detected with the 5 external probe (lower
panel). /, wild-type embryonic stem cells.












grounds, indicating that all K-rastm4A/tm4A mice develop nor-
mally. In addition, further breeding studies found that male
and female K-rastm4A/tm4A offspring were present in the ex-
pected Mendelian ratios in both crossbred (113 and 113, re-
spectively) and inbred (20 and 25, respectively; 21 	 0.556, P
	 0.456) stocks. Male and female K-rastm4A/tm4A mice were
fertile, and females successfully weaned their young.
Detailed histopathological analysis was undertaken of 24
crossbred mice at 3 months, including 12 wild-type and 12
K-rastm4A/tm4A mice, with six males and six females in each
cohort. No abnormalities were detected at necropsy, and ex-
amination of liver, kidney, large and small intestine, stomach,
pancreas, spleen, thymus, heart, lung, brain, ovary, uterus,
seminal vesicles, and testis found no difference between
tissues from wild-type and K-rastm4A/tm4A mice. Inbred
K-rastm4A/tm4A mice were also fertile and outwardly healthy,
and histopathological analysis of a single animal at 3 months
found no abnormalities. The oldest K-rastm4A/tm4A mice in
the crossbred colony are currently 8 months old, and these too
are outwardly healthy.
K-ras 4A-deficient mice express the K-ras 4B splice variant
only. To confirm that the modification of the K-ras gene, by the
introduction of the targeting vector, resulted in the deletion of
the K-ras 4A splice variant, RT-PCR was used to examine
K-ras expression in the large intestine of wild-type and
K-rastm4A/tm4A mice. Only the K-ras 4B splice variant was
expressed by K-rastm4A/tm4A mice (Fig. 3).
K-ras 4A expression in wild-type adult mice. To date, the
expression of K-ras 4A has been examined in only a limited
number of adult mouse tissues (22, 30). In the present study,
the analysis was extended further to gain a comprehensive view
of the overall pattern of K-ras 4A expression in wild-type adult
mice. RT-PCR analysis found that K-ras 4A was expressed in
the liver, large and small intestine, stomach, cecum, kidney,
uterus, salivary gland, and seminal vesicles and only at low
levels in the lung, pancreas, and bone marrow cells (Fig. 4). In
FIG. 2. Genotyping of mice. (A) The upper panel shows amplifi-
cation of K-ras exon 4A by PCR. The 72-bp product is present in
wild-type (/, lanes 9 and 10) and K-rastm4A/ (/,lanes 14 and
15) mice, but not in K-rastm4A/tm4A mice (/, lanes 5 and 11). The
lower panel shows amplification of the neomycin cassette by PCR. The
206-bp product is present in K-rastm4A/ and K-rastm4A/tm4A mice
but not in wild-type mice. (B) Confirmation of genotypes by Southern
blotting. Tail DNA digested with HindIII and hybridized with the 3
internal probe (upper panel) gave a 2-kb fragment for the wild-type
allele and a 6-kb fragment from the targeted allele. Only the 6-kb
fragment is present in K-rastm4A/tm4A mice. Digestion with PvuII and
hybridization with the 5 external probe (lower panel) gave a 5-kb band
for the wild-type allele and a 4-kb fragment for the targeted allele.
Only the 4-kb fragment is present in K-rastm4A/tm4A mice.
FIG. 3. Expression of K-ras in the large intestine from wild-type
and K-rastm4A/tm4A mice. RT-PCR analysis of K-ras 4A and 4B
mRNAs with primers positioned in exons 1 and 4B that amplify both
splice variants in the same reaction (22). The 687-bp band corresponds
to K-ras 4A, and the 565-bp band corresponds to K-ras 4B. Wild-type
(/) but not K-rastm4A/tm4A (/) mice express K-ras 4A. Lane M,
100-bp size markers; the major band shown is 600 bp.
FIG. 4. K-ras 4A and 4B expression in adult mouse tissues. The
PCR primers used amplify both K-ras splice variants in the same
reaction (22). The K-ras 4A and 4B mRNAs generate PCR products of
687 and 565 bp, respectively. Tissues: Ht, heart; LI, large intestine; SI,
small intestine; Ki, kidney; Liv, liver; St, stomach; Lu, lung; Ov, ovary;
Ut, uterus; Adr, adrenal gland; Sg, salivary gland; Sp, spleen; Br, brain;
Pan, pancreas; Bm, bone marrow; Th, thymus; Cae, cecum; Sv, seminal
vesicles; Tt, testis. , PCR negative control. *, 100-bp ladder; the
major band shown is 600 bp.












contrast, K-ras 4B was expressed ubiquitously and was the only
isoform expressed in brain, spleen, heart, adrenal gland, thy-
mus, testis, and ovary. While both isoforms were expressed at
similar levels in stomach and large intestine, K-ras 4A was the
major isoform expressed in the cecum.
DISCUSSION
To gain further understanding concerning the role(s) of K-
Ras in development and tissue function, we examined the
pattern of K-ras 4A expression in wild-type adult mouse tissues
and used gene targeting to delete K-ras 4A expression. While
previous studies have established that expression of the K-ras
gene is essential for mouse development (18, 19), here we found
that, even though K-ras 4A is expressed during development
and in adult tissues (22, 30; this study), all K-rastm4A/tm4A
mice on both inbred and crossbred genetic backgrounds devel-
oped normally, and the adult mice are fertile and healthy.
The finding that K-Ras 4A is dispensable for development
suggests that the embryonic lethality of K-ras/ mice (which
do not express either isoform) may result solely from failure of
expression of the K-Ras 4B isoform. However, the very fact
that K-ras 4A is expressed during development, albeit in a
spatially and temporally regulated manner (22), raises the pos-
sibility that the lethal K-ras/ phenotype could result from
loss of synergistic function of the two protein isoforms or else
from loss of a critical function(s) that can be performed by
either isoform, such that one or the other is necessary but in
the absence of both development cannot occur. While the
latter possibility is less likely, given that only the K-Ras 4B
isoform is expressed ubiquitously throughout development
(22), questions concerning whether expression of the K-Ras 4B
isoform is essential for normal development and whether K-
Ras 4A influences its action wait to be addressed by comparing
the phenotypes of K-ras/ and K-ras 4B-deficient mice on the
same inbred genetic background. It is nevertheless important
to stress that whatever the result of these future studies, our
conclusion that K-Ras 4A is dispensable for normal mouse
development in the presence of functional K-Ras 4B remains
valid.
The C-terminal modifications of Ras proteins are essential
for protein function (16), and functional differences between
Ras proteins may reflect, at least in part, these different mod-
ifications. Therefore, the findings by Hancock et al. that N-, H-,
and K-Ras 4A undergo similar C-terminal modifications which
involve palmitoylation of cysteine residues upstream of the
common CAAX motif (14) are significant because these pro-
teins are dispensable for normal development. Furthermore,
the viability of K-rastm4A/tm4A mice is unlikely to reflect a
compensatory upregulation of these closely related Ras pro-
teins, since the simultaneous deletion of both K-ras splice
variants does not result in the upregulation of H-ras or N-ras
expression in either tissues or fibroblast cultures from K-ras/
embryos (18). Likewise, H-ras/ N-ras/ mutant mice show
no change in K-ras expression (10).
Importantly, since N-ras/, H-ras/, and K-rastm4A/tm4A
mice are fertile, it is now possible, by crossing these mice, to
formally test whether the viability of K-rastm4A/tm4A mice is
indeed independent of N- and H-ras expression. Also, since
K-Ras 4B, unlike K-Ras 4A, associates with the plasma mem-
brane by virtue of a polybasic domain and, thereby, may local-
ize to different membrane microdomains, it could selectively
activate Ras effectors required for embryonic development.
Indeed, Ras proteins, including the K-Ras isoforms, differen-
tially activate particular downstream effectors (28, 29, 31).
Since K-rastm4A/tm4A mice are viable, their analysis can also
address whether both K-Ras isoforms differentially affect Ras
effector signal transduction pathways in vivo. This information
is crucial in view of current research interest in anti-Ras agents,
some of which target posttranslational modifications that affect
one isoform and not the other, in cancer therapy (2).
Previous studies based on RT-PCR and Northern blotting
reported that K-ras 4A is expressed in adult liver, stomach,
small intestine, colon, and kidney but disagree concerning its
expression in the lung (22, 30). Furthermore, these studies
reported that K-ras 4A is invariably the minor isoform ex-
pressed. The present findings that K-ras 4A is expressed in a
wide range of adult tissues, including lung and in some cases at
levels equal to or greater than that of K-ras 4B (Fig. 4) imply
it has an important role in tissue homeostasis in general, even
though it is dispensable for normal development. In view of
recent reports that N-ras/ and H-ras/ mice exhibit phe-
notypes but only after challenge with exogenous agents (6, 15),
a similar approach with K-rastm4A/tm4A mice, combined with
examination of the long-term consequence of K-Ras 4A-defi-
ciency, may yield insight concerning the role(s) of K-Ras 4A in
tissue function.
The finding that K-Ras 4A is dispensable for development
also presents an opportunity to examine the role of the K-Ras
isoforms in tumorigenesis in vivo. While expression of a mu-
tationally activated K-ras 4B transgene can promote develop-
ment of lung and intestinal tumors (12, 17), evidence suggests
that mutant K-Ras 4A could also be implicated in tumorigen-
esis: (i) expression of a K-ras 4A transgene encoding an acti-
vating mutation can transform cells in vitro and with greater
efficiency than K-ras 4B (28); (ii) mutationally activated K-ras
4A is expressed by the SW480 human colorectal carcinoma cell
line (5); (iii) the level of K-ras 4A expression in lung correlates
with lung tumor susceptibility among inbred mouse strains
(30); and (iv) here we found that K-ras 4A is expressed in the
colon, lung. and pancreas, where tumors with K-ras activating
mutations generally arise in human malignancy (1). Since mu-
tant K-Ras isoforms differ in their ability to promote cell trans-
formation and cell migration (28), it is conceivable that syner-
gistic interactions between activated K-Ras 4A and K-Ras 4B
could play a crucial role in driving tumor development. In view
of recent evidence that wild-type K-Ras exhibits tumor sup-
pressor activity (32), K-rastm4A/tm4A mice can be used to
address not only the role of K-Ras 4A in neoplastic progres-
sion in vivo, but also whether both isoforms exhibit tumor
suppressor activity.
Examination of the role of wild-type K-Ras in adult tissues,
where tumors with oncogenic K-ras mutations normally arise,
is one approach to gain valuable insight concerning how these
mutations promote tumorigenesis. While this has been hin-
dered by the embryonic lethality of the K-ras null mutation (18,
19), we envisage that future studies with K-rastm4A/tm4A mice
will contribute significantly to understanding why K-ras acti-
vating mutations are so prevalent in human malignancies and












why they are linked with particular types of epithelial cell-
derived tumors.
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